Background
Methodology
Data collection and screening
Statistical analysis
Validation in 205 patients using IHC
Results
Expression analysis of FGFR genes in discovery cohort 1
Association between FGFR genes and clinical features in discovery cohort 1
Gene name | Hazard ratio (95% CI) | P value |
---|---|---|
FGFR1
| 0.475 (0.277–0.817) | 0.007 |
FGFR4
| 0.610 (0.370–1.008) | 0.054 |
FGF19
| 1.029 (0.630–1.682) | 0.908 |
FGF21
| 0.853 (0.515–1.413) | 0.537 |
KLB
| 0.536 (0.318–0.903) | 0.019 |
Factors | Hazard ratio (95% CI) | P value |
---|---|---|
FGFR1
| ||
FGFR1 (high vs. low) | 0.524 (0.281–0.977) | 0.042 |
Tumor grade (1, 2 vs. 3, 4) | 0.585 (0.337–1.016) | 0.057 |
Tumor stage (1, 2 vs. 3, 4) | 0.814 (0.427–1.548) | 0.530 |
FGFR4
| ||
FGFR4 (high vs. low) | 0.975 (0.516–1.842) | 0.937 |
Tumor grade (1, 2 vs. 3, 4) | 0.514 (0.263–1.002) | 0.051 |
Tumor stage (1, 2 vs. 3, 4) | 1.109 (0.614–2.001) | 0.732 |
KLB
| ||
KLB (high vs. low) | 0.640 (0.375–1.093) | 0.102 |
Tumor grade (1, 2 vs. 3, 4) | 0.547 (0.316–0.945) | 0.031 |
Tumor stage (1, 2 vs. 3, 4) | 1.082 (0.606–1.931) | 0.791 |
Expression and survival analysis of FGFR genes in discovery cohort 2
Expression and survival analysis of FGFR genes in discovery cohort 3
FGFR1 immunolabeling in the validation cohort
Univariate and multivariate analysis for overall survival
P value | HR | Univariate Analysis | P value | HR | Multivariate analysis | |||
---|---|---|---|---|---|---|---|---|
95.0% CI for HR | 95.0% CI for HR | |||||||
Lower | Upper | Lower | upper | |||||
Age, years (≥ 60 vs. < 60) | 0.016 | 1.451 | 1.073 | 1.961 | 0.008 | 1.587 | 1.130 | 2.230 |
Gender | 0.235 | 1.191 | 0.892 | 1.591 | ||||
Tumor size, cm (≥ 2 vs. < 2) | 0.241 | 1.534 | 0.751 | 3.135 | ||||
Differentiation (well/moderate vs. poor) | 0.076 | 1.428 | 0.964 | 2.115 | ||||
Extension (confined vs. peripancreatic soft tissue) | 0.061 | 1.898 | 0.970 | 3.714 | ||||
Bile duct invasion (absent vs. present) | 0.009 | 1.469 | 1.099 | 1.963 | 0.002 | 1.657 | 1.211 | 2.269 |
Duodenum invasion (absent vs. present) | 0.074 | 1.303 | 0.975 | 1.742 | ||||
Lymphovascular invasion (absent vs. present) | 0.011 | 1.455 | 1.088 | 1.944 | 0.098 | 1.320 | .950 | 1.834 |
Perineural invasion (absent vs. present) | 0.086 | 1.403 | .953 | 2.064 | ||||
Lymph node metastasis (absent vs. present) | < 0.001 | 2.495 | 1.811 | 3.436 | < 0.0001 | 2.360 | 1.665 | 3.344 |
Tumor stagea | 0.059 | 1.382 | 0.988 | 1.933 | ||||
FGFR1 (positive vs. negative) | 0.003 | 0.590 | 0.415 | 0.839 | 0.035 | 0.677 | 0.471 | 0.972 |